晚期肾细胞癌-话题@MedSci

#晚期肾细胞癌#

45篇内容 | 2348人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1441760, encodeId=6c501441e6036, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=FDA批准Opdivo联合Cabometyx用于治疗晚期肾细胞癌, objectType=article, longId=206187, objectId=73a020618e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73a020618e5c, replyNumber=0, likeNumber=74, createdTime=2021-01-26, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73a020618e5c, moduleTitle=FDA批准Opdivo联合Cabometyx用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73a020618e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441759, encodeId=de121441e593f, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Nat Med：阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析, objectType=article, longId=201119, objectId=02dd201119b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02dd201119b7, replyNumber=0, likeNumber=70, createdTime=2020-09-25, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02dd201119b7, moduleTitle=Nat Med：阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02dd201119b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441758, encodeId=ad911441e58d3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较, objectType=article, longId=186219, objectId=9cd3186219f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cd3186219f9, replyNumber=0, likeNumber=77, createdTime=2020-01-15, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cd3186219f9, moduleTitle=Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cd3186219f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441757, encodeId=2ce41441e57fd, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗, objectType=article, longId=185318, objectId=3122185318dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3122185318dd, replyNumber=0, likeNumber=37, createdTime=2019-12-28, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3122185318dd, moduleTitle=2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3122185318dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441756, encodeId=a8c51441e56ec, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗, objectType=article, longId=178980, objectId=52fd1e8980a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52fd1e8980a7, replyNumber=0, likeNumber=58, createdTime=2019-09-07, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52fd1e8980a7, moduleTitle=PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52fd1e8980a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441755, encodeId=3b3d1441e5543, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Lancet oncol：纳武单抗联合易普利姆玛治疗晚期肾细胞癌患者的长期疗效, objectType=article, longId=178029, objectId=317c1e802913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317c1e802913, replyNumber=0, likeNumber=68, createdTime=2019-08-22, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317c1e802913, moduleTitle=Lancet oncol：纳武单抗联合易普利姆玛治疗晚期肾细胞癌患者的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317c1e802913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441754, encodeId=6ac51441e5409, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定, objectType=article, longId=176035, objectId=15c61e603593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c61e603593, replyNumber=0, likeNumber=70, createdTime=2019-07-25, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c61e603593, moduleTitle=英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c61e603593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441753, encodeId=31e81441e5327, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势, objectType=article, longId=166310, objectId=318316631011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=318316631011, replyNumber=0, likeNumber=68, createdTime=2019-05-20, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=318316631011, moduleTitle=CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=318316631011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441752, encodeId=9a881441e5237, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, objectType=article, longId=166173, objectId=9b091661e313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b091661e313, replyNumber=0, likeNumber=106, createdTime=2019-05-17, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b091661e313, moduleTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b091661e313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441751, encodeId=c7421441e515a, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=ARCH PATHOL LAB MED：染色体基因组阵列检测在未分类晚期肾细胞癌中的临床应用, objectType=article, longId=165773, objectId=03bd165e73c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03bd165e73c2, replyNumber=0, likeNumber=100, createdTime=2019-05-11, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03bd165e73c2, moduleTitle=ARCH PATHOL LAB MED：染色体基因组阵列检测在未分类晚期肾细胞癌中的临床应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03bd165e73c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441750, encodeId=fdaf1441e50ce, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=NEJM：Avelumab加阿西替尼与舒尼替尼治疗晚期肾细胞癌的疗效比较, objectType=article, longId=162682, objectId=970d162682a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970d162682a2, replyNumber=0, likeNumber=89, createdTime=2019-03-22, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970d162682a2, moduleTitle=NEJM：Avelumab加阿西替尼与舒尼替尼治疗晚期肾细胞癌的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970d162682a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441749, encodeId=f3df1441e49b6, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=NEJM：派姆单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌疗效比较, objectType=article, longId=162681, objectId=6ab8162681a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ab8162681a7, replyNumber=0, likeNumber=101, createdTime=2019-03-22, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ab8162681a7, moduleTitle=NEJM：派姆单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ab8162681a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441748, encodeId=c68a1441e482c, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=94, createdTime=2019-03-10, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441747, encodeId=7d741441e4718, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=KEYTRUDA（pembrolizumab）与Inlyta（阿西替尼）组合显著降低了晚期肾细胞癌患者的死亡风险, objectType=article, longId=160426, objectId=a9a11604268e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a11604268e, replyNumber=0, likeNumber=97, createdTime=2019-02-20, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a11604268e, moduleTitle=KEYTRUDA（pembrolizumab）与Inlyta（阿西替尼）组合显著降低了晚期肾细胞癌患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a11604268e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441746, encodeId=a56f1441e46ed, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, objectType=article, longId=160425, objectId=2800160425be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2800160425be, replyNumber=0, likeNumber=129, createdTime=2019-02-20, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2800160425be, moduleTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2800160425be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441745, encodeId=f7521441e4503, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准, objectType=article, longId=158125, objectId=cd04158125a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd04158125a7, replyNumber=0, likeNumber=70, createdTime=2019-01-17, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd04158125a7, moduleTitle=喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd04158125a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441744, encodeId=7c0a1441e44e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=CLIN CANCER RES：镭223联合VEGF靶向疗法治疗晚期肾细胞癌, objectType=article, longId=148296, objectId=cc7714829642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc7714829642, replyNumber=0, likeNumber=54, createdTime=2018-09-07, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc7714829642, moduleTitle=CLIN CANCER RES：镭223联合VEGF靶向疗法治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc7714829642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效：III期交叉研究, objectType=article, longId=136869, objectId=073213686943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=073213686943, replyNumber=0, likeNumber=68, createdTime=2018-05-01, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=073213686943, moduleTitle=tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效：III期交叉研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=073213686943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441742, encodeId=44f11441e425e, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Brit J Cancer：在晚期肾细胞癌中，卡博替尼和依维莫司药物治疗的总生存长期跟踪调查研究, objectType=article, longId=134402, objectId=a08413440202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a08413440202, replyNumber=0, likeNumber=62, createdTime=2018-04-08, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a08413440202, moduleTitle=Brit J Cancer：在晚期肾细胞癌中，卡博替尼和依维莫司药物治疗的总生存长期跟踪调查研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a08413440202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441741, encodeId=61101441e4106, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Lancet oncol：阿西替尼联合派姆单抗治疗晚期肾细胞癌患者的安全性和效果, objectType=article, longId=129653, objectId=ed1312965394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed1312965394, replyNumber=0, likeNumber=51, createdTime=2018-02-13, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed1312965394, moduleTitle=Lancet oncol：阿西替尼联合派姆单抗治疗晚期肾细胞癌患者的安全性和效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed1312965394)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期肾细胞癌

2020-05-29

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

FDA批准Opdivo联合Cabometyx用于治疗晚期肾细胞癌

2021-01-26

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Nat Med：阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析

2020-09-25

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Lancet Oncol：晚期肾细胞癌中tivozanib和sorafenib治疗比较

2020-01-15

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

2019 SITC共识声明：晚期肾细胞癌（RCC）免疫治疗

2019-12-28

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

PD-1单抗Keytruda又一重大突破：与阿西替尼联合获欧盟批准用作晚期肾细胞癌（RCC）的一线治疗

2019-09-07

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Lancet oncol：纳武单抗联合易普利姆玛治疗晚期肾细胞癌患者的长期疗效

2019-08-22

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定

2019-07-25

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

CTLA4单抗ipilimumab和PD-1单抗nivolumab联合的临床研究证实：该药物组合对晚期肾细胞癌患有明显治疗优势

2019-05-20

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌

2019-05-17

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

ARCH PATHOL LAB MED：染色体基因组阵列检测在未分类晚期肾细胞癌中的临床应用

2019-05-11

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

NEJM：Avelumab加阿西替尼与舒尼替尼治疗晚期肾细胞癌的疗效比较

2019-03-22

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

NEJM：派姆单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌疗效比较

2019-03-22

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-03-10

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

KEYTRUDA（pembrolizumab）与Inlyta（阿西替尼）组合显著降低了晚期肾细胞癌患者的死亡风险

2019-02-20

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据

2019-02-20

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

喜大普奔|纳武利尤单抗联合低剂量伊匹木单抗一线治疗中高危晚期肾细胞癌获欧盟委员会批准

2019-01-17

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

CLIN CANCER RES：镭223联合VEGF靶向疗法治疗晚期肾细胞癌

2018-09-07

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效：III期交叉研究

2018-05-01

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Brit J Cancer：在晚期肾细胞癌中，卡博替尼和依维莫司药物治疗的总生存长期跟踪调查研究

2018-04-08

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Lancet oncol：阿西替尼联合派姆单抗治疗晚期肾细胞癌患者的安全性和效果

2018-02-13

科室
- - 订阅+
  - 更多科室
工具
服务